Hot Topics in Heart Failure: New Data and Therapies That Are Changing the Treatment Landscape

Hear these expert faculty members as they discuss their latest insights on SGLT2 inhibitors in HFrEF, timing of ARNI initiation in decompensated HF, and more.
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Javed Butler, MD, MPH, MBA

Downloadable Slideset

See the latest insights on SGLT2 inhibitors in HF, emerging therapies in HFrEF, timing of ARNI initiation in decompensated HF, and more.

Released: December 9, 2020

On-Demand Webcast

Hear these expert faculty as they discuss questions such as, “Do outcomes from DAPA-HF and EMPEROR-Reduced suggest a class effect of SGLT2 inhibitors?” “Is it safe to start ARNI in the hospital, and does it influence post discharge outcomes?” “What is the likely place of emerging therapies like vericiguat and omecamtiv mecarbil in HFrEF?”

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Javed Butler, MD, MPH, MBA Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 15, 2020 Expired: December 14, 2021
Provided by Clinical Care Options

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by an educational grant from
Merck

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue